Relmada Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2012 | $-7.6K | $-1.6M | — | $37.3K |
| FY2013 | $-11.9K | $-2.2M | $-1.8K | $382.3K |
| FY2015 | $-16.2M | $-16.3M | $23.3K | $797.0K |
| FY2016 | $-13.1M | $-13.7M | $562.3K | $1.0M |
| FY2017 | $-6.5M | $-6.5M | $49.7K | $704.5K |
| FY2018 | $-6.0M | $-6.0M | $12.4K | $518.0K |
| FY2019 | $-10.5M | $-96.9M | $84.8M | $3.2M |
| FY2020 | $-27.8M | $-209.9M | $182.1M | $20.8M |
| FY2021 | $-91.9M | $-91.9M | — | $40.5M |
| FY2022 | $-103.8M | $-103.8M | — | $44.2M |
| FY2023 | $-51.7M | $-51.7M | — | $43.8M |
| FY2024 | $-51.8M | $-51.8M | — | $30.2M |
| FY2025 | $-45.8M | $-45.8M | — | $13.9M |